logo
Why Americans who live near coastlines and lakefronts may face heightened ALS risk

Why Americans who live near coastlines and lakefronts may face heightened ALS risk

Yahoo14 hours ago

If you live near bodies of water frequently impacted by harmful algal blooms, you may be at an increased risk of dying from ALS, new research reveals.
Amyotrophic lateral sclerosis, the debilitating neurodegenerative disease commonly known as 'Lou Gehrig's Disease,' is influenced by genetics and environmental factors. It dramatically slashes the patient's life expectancy, with people typically passing away within two to five years of diagnosis.
Some 5,000 are diagnosed with ALS each year in the U.S., and there are approximately 15 new cases each day. Recently, Grey's Anatomy star Eric Dane announced he was battling the disease and told Good Morning America that his body's right side had 'completely stopped working.'
Now, researchers at the University of Michigan Medicine say toxins produced by algal blooms in lakes and along American coasts could influence disease progression.
'While there is still limited research into the mechanism by which cyanobacteria toxins affect neurodegenerative diseases, our findings suggest that living near or participating in activities in these water bodies may influence the progression of ALS,' Dr. Stephen Goutman, the school's Harriet Hiller research professor, director of the Pranger ALS Clinic, and associate director of the ALS Center of Excellence, said in a statement.
Goutman is the senior author of the study which was published in the International Journal of Environmental Research and Public Health.
Specifically, the researchers have found a toxin produced by the bloom cyanobacteria in brain and spinal fluid cerebral spinal fluid samples of people with ALS. It's known as ß-methylamino-L-alanine.
Increasingly driven by human-caused climate change and nutrient pollution, the blooms are caused when cyanobacteria grows dense and out of control. Cyanobacteria produce several toxic agents that are linked neurodegenerative diseases, including Alzheimer's and Parkinson's.
They surveyed participants who were seen at the University of Michigan Pranger ALS Clinic, many of whom lived within three miles of a harmful algal bloom. They measured the duration and extent of their exposure using satellite data from the Cyanobacteria Assessment Network and their residential and health histories.
Ultimately, they found that living near blooms -- especially if swimming or boating -- was associated with dying of ALS nearly one year sooner. The people with the most significant exposures both lived near harmful blooms and used a private well as their water source.
People in the Midwest may be particularly threatened partially due to pervasive industrial and agricultural productions in the region. Michigan's Lake Erie is frequently impacted by these blooms.
'If exposure to cyanobacteria toxins is a meaningful risk factor for ALS, the large number of inland lakes from to such bacteria in the Midwest may partly explain why the disease incidence is much higher than other parts of the country,' Dr. Stuart Batterman, first author and professor of environmental health sciences at the university's School of Public Health, said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

McCarthy, Jacobs finish construction on $373M hospital tower
McCarthy, Jacobs finish construction on $373M hospital tower

Yahoo

timean hour ago

  • Yahoo

McCarthy, Jacobs finish construction on $373M hospital tower

This story was originally published on Construction Dive. To receive daily news and insights, subscribe to our free daily Construction Dive newsletter. A team of McCarthy Building Cos. and Jacobs completed construction on the Children's Hospital of Orange County's Southwest Tower in Orange, California, according to a June 16 news release from CannonDesign, the New York City-based engineer on the project. McCarthy acted as the general contractor, with Dallas-based Jacobs as the construction manager. St. Louis-based McCarthy broke ground on the nine-story, 300,000-square-foot facility in 2022. The cost of the project was estimated to be around $373 million in 2023, according to the Orange County Business Journal. It was designed to complement the hospital's Bill Holmes Tower, which McCarthy completed in 2012 with CannonDesign as architect. 'This facility enables McCarthy Building Companies to leverage our deep well of expertise in the healthcare sector that will have a positive impact well beyond the scope of this project,' said Jim Madrid, president of the Southern Pacific region for McCarthy, in the groundbreaking news release. The new tower houses a number of pediatric outpatient services that include, according to the news release: Five floors of specialty clinics. A research institute for clinical trials and pediatric research. Oncology infusion services. A comprehensive imaging center. Craig Cherf, a senior preconstruction director who worked on both the Southwest and the Bill Holmes towers, has a personal connection to the hospital. Cherf's son Jackson, then 4, was diagnosed with and treated for acute lymphoblastic leukemia at the hospital's Hyundai Cancer Institute, according to a blog post from the hospital. Jackson is now cancer-free. 'I love working on children's hospitals,' Cherf said in the 2024 blog post. 'It's my favorite thing to do.' Alongside the opening of the outpatient tower, CHOC opened a 24-bed cardiovascular intensive care unit and a 28-bed neuroscience unit within the Bill Holmes Tower to meet increased demand for these high-acuity services, according to CannonDesign. Recommended Reading Building team selected for $895M Portland, Oregon, span

Encompass Health Plans a 50-Bed Unit to Better Serve North Las Vegas
Encompass Health Plans a 50-Bed Unit to Better Serve North Las Vegas

Yahoo

timean hour ago

  • Yahoo

Encompass Health Plans a 50-Bed Unit to Better Serve North Las Vegas

Encompass Health Corporation EHC recently disclosed initial plans to construct a freestanding inpatient rehabilitation hospital in North Las Vegas, NV. Equipped with 50 beds, the facility is expected to commence operations by 2028. The hospital will offer private patient rooms, a modern therapy gym equipped with advanced rehabilitation technologies and specialized spaces such as daily living suite and an in-house dialysis unit. Complementing these are additional amenities like an in-house pharmacy, a communal dining space and a therapeutic courtyard. Patients will benefit from comprehensive rehabilitative services, including round-the-clock nursing care, as well as physical, occupational and speech therapy. The care team will include highly trained physicians, therapists and nurses. This, in turn, will ensure speedy recovery of patients suffering from a range of serious health conditions and ensure their quicker return to normal daily activities. Encompass Health's latest announcement highlights its commitment to enhancing healthcare outcomes in the Las Vegas region, thereby reinforcing its presence throughout Nevada, where it operates three other facilities. These expansion efforts are driven by a sustained need for comprehensive rehabilitation services across various U.S. communities. By continually growing its nationwide network of inpatient rehabilitation hospitals, Encompass Health positions itself to serve an expanding patient population and generate increased revenues. Higher patient volumes boost revenues for any healthcare operator like EHC. In the first quarter of 2025, Encompass Health reported $1.5 billion in revenues from inpatient rehabilitation services, reflecting 10.6% year-over-year growth. Currently, the company operates 168 inpatient rehabilitation hospitals across 38 states and Puerto Rico. This expansive portfolio is the result of a proactive growth strategy that includes both independently developed facilities and also facilities built through partnerships with regional healthcare providers. These collaborations offer strategic advantages by enabling Encompass Health to gain deeper insights into the unique healthcare needs of different regions. The last addition to its hospital portfolio was that of Rehabilitation Hospital of Fort Myers, which was built in partnership with Lee Health to provide high-quality rehabilitation services across Florida. Shares of Encompass Health have gained 41.8% in the past year compared with the industry's 3.6% growth. EHC currently sports a Zacks Rank #1 (Strong Buy). Image Source: Zacks Investment Research Some other top-ranked stocks in the Medical space are Integer Holdings Corporation ITGR, Align Technology, Inc. ALGN and BioLife Solutions, Inc. BLFS, each currently sporting a Zacks Rank of 1. You can see the complete list of today's Zacks #1 Rank stocks here. Integer's earnings surpassed estimates in three of the last four quarters and missed the mark once, the average surprise being 2.77%. The Zacks Consensus Estimate for ITGR's 2025 earnings indicates a rise of 19.4%, while the consensus mark for revenues implies an improvement of 7.7% from the respective prior-year tallies. The consensus mark for ITGR's 2025 earnings has moved 4.5% north in the past 60 bottom line of Align Technology outpaced estimates in each of the trailing four quarters, the average beat being 3.40%. The Zacks Consensus Estimate for ALGN's 2025 earnings indicates a rise of 10.7%, while the consensus mark for revenues implies an improvement of 3.9% from the respective prior-year tallies. The consensus mark for ALGN's 2025 earnings has moved 4.2% north in the past 60 days. BioLife Solutions' earnings outpaced estimates in each of the trailing four quarters, the average surprise being 112.90%. The Zacks Consensus Estimate for BLFS' 2025 earnings is pegged at 2 cents per share. A loss of 7 cents per share was incurred in the prior-year quarter. BLFS has witnessed one upward estimate revision for 2025 earnings against none down in the past 60 days. Shares of Integer and BioLife Solutions have gained 2.8% and 3.3%, respectively, in the past year. However, Align Technology stock has lost 25.8% in the same time frame. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report BioLife Solutions, Inc. (BLFS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Encompass Health Corporation (EHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BMJ Investigation Increases Concerns About Ticagrelor Trials
BMJ Investigation Increases Concerns About Ticagrelor Trials

Medscape

timean hour ago

  • Medscape

BMJ Investigation Increases Concerns About Ticagrelor Trials

An investigation by The BMJ is raising fresh concerns about the clinical studies that supported the approval of the antiplatelet drug ticagrelor (Brilinta, AstraZeneca), almost 15 years after the medication was first approved and as generic versions are set to hit the market. Peter Doshi, PhD, a senior editor at The BMJ , previously reported inconsistencies and omissions in data reporting from the 2009 PLATO study, published in The New England Journal of Medicine , which showed ticagrelor was superior to clopidogrel in treating acute coronary syndrome. Now a follow-up investigation of two supporting studies published in Circulation , ONSET/OFFSET and RESPOND, has revealed primary endpoints were reported inaccurately, data were missing from the submission to the US Food and Drug Administration (FDA), and study centers may not have received adequate training. Doshi said the results of his investigations call into question the drug's approval and suggested that it should be revisited. 'The FDA's approval in 2011 went against the evidence according to its reviewers, and now, my investigations into PLATO, ONSET/OFFSET, and RESPOND, suggest that even the data presented to the FDA and reported in The New England Journal of Medicine and Circulation , is not trustworthy,' he told Medscape Medical News. The investigation identified several problems with data integrity in the two trials. The original primary endpoint results for RESPOND, which aimed to test whether ticagrelor could convert nonresponders to clopidogrel into responders, were statistically nonsignificant ( P = .157) but were subsequently reported in Circulation as significant ( P = .005) because of an undeclared change in its primary endpoint definition. For ONSET/OFFSET, which reported ticagrelor provided faster and greater inhibition of platelets than clopidogrel, the investigators now claim several patients were excluded from the analysis. However, those who remained were identified as the 'intention-to-treat' population, implying all patients were included. Implausible data points were also included in the analysis of the primary endpoint but were first transformed through an unpublished data analysis, Doshi claimed. Doshi also gained access to readouts from some of the platelet function test machines used in the trial. He found more than 60 of 282 readings were not present in the datasets submitted to the FDA, and the levels of platelet activity in those readings were significantly higher than those reported in Circulation . Victor Serebruany, MD, from Johns Hopkins University in Baltimore, and one of the more high-profile critics of ticagrelor, told The BMJ the missing readings show 'there are episodes of skyrocketing rebound and profound platelet inhibition after ticagrelor, making patients prone to thrombosis or bleeding. If doctors had known what happened in these trials, they would never have started using ticagrelor.' The investigation also revealed oddities around the authorship of the publications. One active trial investigator was never identified as a study author, while one author told The BMJ he was not involved in the trial. The BMJ states that AstraZeneca, the journal Circulation , and many of the original investigators either declined to comment on the new claims or were unreachable. Ticagrelor has been under fire since the beginning. The drug failed in its first bid for FDA approval and was the subject of an investigation by the US Department of Justice in 2013 at the urging of Serebruany. That investigation was closed in 2014 with no further action. A review of several major trials of ticagrelor by Eric Bates, MD, professor of internal medicine at the University of Michigan in Ann Arbor, Michigan, and a co-author of the US guidelines that recommend ticagrelor, concluded 'the clinical conventional wisdom and clinical trial guideline support for…ticagrelor compared with clopidogrel may be overemphasized.' Bates is now calling for a review of ticagrelor's recommendation in guidelines, according to the earlier The BMJ report.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store